Non-infectious pediatric uveitis: An update on immunomodulatory management

Pediatric Drugs

Volumn 11, Issue 4, 2009, Pages 229-241

  Sharma, Srilakshmi M ^a   Dick, Andrew D ^b   Ramanan, Athimalaipet V ^c  

^a BRISTOL EYE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; ALPHA2A INTERFERON; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIMETABOLITE; AZATHIOPRINE; CALCINEURIN INHIBITOR; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOPLEGIC AGENT; CYCLOSPORIN A; DACLIZUMAB; ETANERCEPT; FLUOCINOLONE ACETONIDE; FOLIC ACID; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE ACETATE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RIMEXOLONE; TACROLIMUS; TRIAMCINOLONE ACETONIDE; TRIAMCINOLONE HEXACETONIDE; UNINDEXED DRUG;

ADD ON THERAPY; ALLERGIC REACTION; ANOREXIA NERVOSA; BLAU SYNDROME; BONE MARROW TOXICITY; CATARACT; CLINICAL TRIAL; DEMYELINATION; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG WITHDRAWAL; ENZYME INHIBITION; FATIGUE; FEVER; FLU LIKE SYNDROME; GONADAL DISEASE; HEPATITIS B; HERNIA; HUMAN; HYPERURICEMIA; IMMUNOMODULATION; INFLAMMATION; INFLAMMATORY DISEASE; JUVENILE RHEUMATOID ARTHRITIS; LEUKOPENIA; LOW DRUG DOSE; LYMPHOCYTOPENIA; MORNING DOSAGE; MUCKLE WELLS SYNDROME; MUSCLE SPASM; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OPTIC NERVE DISEASE; PERFORATING EYE INJURY; PRIORITY JOURNAL; PTOSIS; REVIEW; SARCOIDOSIS; SIDE EFFECT; STRABISMUS; TREATMENT OUTCOME; UVEITIS; VOMITING;

ANTI-INFLAMMATORY AGENTS; CHILD; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; UVEITIS;

EID: 69749106862     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.2165/00148581-200911040-00002     Document Type: Review

References (120)

1. Zierhut M, Michels H, Stubiger N, et al. Uveitis in children. Int Ophthalmol Clin 2005; 45: 135-156
2. Paivonsalo-Hietanen T, Tuominen J, Saari KM. Uveitis in children: population-based study in Finland. Acta Ophthalmol Scand 2000; 78: 84-88 (Pubitemid 30095319)
3. Cunningham Jr ET. Uveitis in children. Ocul Immunol Inflamm 2000; 8: 251-261
4. Sudharshan S, Biswas J, Ganesh SK. Analysis of juvenile idiopathic arthritis associated uveitis in India over the last 16 years. Indian J Ophthalmol 2007; 55: 199-202
5. De Boer J, Wulffraat N, Rothova A. Visual loss in uveitis of childhood. Br J Ophthalmol 2003; 87: 879-884
6. Edelsten C, Reddy MA, Stanford MR, et al. Visual loss associated with pediatric uveitis in english primary and referral centers. Am J Ophthalmol 2003; 135: 676-680 (Pubitemid 36457974)
7. Kanski JJ, Shun-Shin GA. Systemic uveitis syndromes in childhood: an analysis of 340 cases. Ophthalmology 1984; 91: 1247-1252
8. Rothova A, Suttorp-van Schulten MS, Frits Treffers W, et al. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 1996; 80: 332-336 (Pubitemid 26113585)
9. Tugal-Tutkun I, Havrlikova K, Power WJ, et al. Changing patterns in uveitis of childhood. Ophthalmology 1996; 103: 375-383
10. Wright T, Cron RQ. Pediatric rheumatology for the adult rheumatologist. II: uveitis in juvenile idiopathic arthritis. J Clin Rheumatol 2007; 13: 205-210 (Pubitemid 47356789)
11. Smith JR. Management of uveitis in pediatric patients: special considerations. Paediatr Drugs 2002; 4: 183-189 (Pubitemid 34293253)
12. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data: results of the first international workshop. Am J Ophthalmol 2005; 140: 509-516
13. Yu EN, Meniconi ME, Tufail F, et al. Outcomes of treatment with immunomodulatory therapy in patients with corticosteroid-resistant juvenile idiopathic arthritis-associated chronic iridocyclitis. Ocul Immunol Inflamm 2005; 13: 353-360 (Pubitemid 41702758)
14. Lacomba MS, Martin CM, Chamond RR, et al. Aqueous and serum interferon gamma, interleukin (IL) 2, IL-4, and IL-10 in patients with uveitis. Arch Ophthalmol 2000; 118: 768-772
15. Chalom EC, Goldsmith DP, Koehler MA, et al. Prevalence and outcome of uveitis in a regional cohort of patients with juvenile rheumatoid arthritis. J Rheumatol 1997; 24: 2031-2034
16. Soylu M, Ozdemir G, Anli A. Pediatric uveitis in southern Turkey. Ocul Immunol Inflamm 1997; 5 (3): 197-202
17. Kump LI, Cervantes-Castañeda RA, Androudi SN, et al. Analysis of pediatric uveitis cases at a tertiary referral center. Ophthalmology 2005 Jul; 112 (7): 1287-1292
18. Ng JSK, Fan DSP, Young AL, et al. Ocular hypertensive response to topical dexamethasone in children: a dose-dependent phenomenon. Ophthalmology 2000; 107: 2097-2100
19. Stanbury RM, Graham EM, Systemic corticosteroid therapy: side effects and their management. Br J Ophthalmol 1998 Jun; 82 (6): 704-708 (Pubitemid 28306665)
20. Smith JR, George RK, Rosenbaum JT. Lower eyelid herniation of orbital fat may complicate periocular corticosteroid injection. Am J Ophthalmol 2002; 133: 845-847
21. Sivaprasad S, McCluskey P, Lightman S. Intravitreal steroids in the management of macular oedema. Acta Ophthalmol Scand 2006; 84: 722-733 (Pubitemid 44688319)
22. Chang J, McCluskey PJ, Grigg JR, et al. Safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular oedema in children. Clin Experiment Ophthalmol 2006; 34: A59-68
23. Zulian F, Martini G, Gobber D, et al. Triamcinolone acetonide and hexacetonide intra-articular treatment of symmetrical joints in juvenile idiopathic arthritis: a double-blind trial. Rheumatology (Oxford) 2004; 43: 1288-1291 (Pubitemid 39359306)
24. Eberhard BA, Sison MC, Gottlieb BS, et al. Comparison of the intraarticular effectiveness of triamcinolone hexacetonide and triamcinolone acetonide in treatment of juvenile rheumatoid arthritis. J Rheumatol 2004; 31: 2507-2512 (Pubitemid 39603105)
25. Sijssens KM, Rothova A, Berendschot TTJM, et al. Ocular hypertension and secondary glaucoma in children with uveitis. Ophthalmology 2006; 113: 853-859
26. Jaffe GJ, Martin D, Callanan D, et al. Fluocinolone acetonide implant (retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006; 113: 1020-1027 (Pubitemid 43795240)
27. Foeldvari I, Wierk A. Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J Rheumatol 2005; 32: 362-365 (Pubitemid 40209138)
28. Malik AR, Pavesio C. The use of low dose methotrexate in children with chronic anterior and intermediate uveitis. Br J Ophthalmol 2005; 89: 806-808 (Pubitemid 40904797)
29. Berker N, Ozdamar Y, Soykan E, et al. Vogt-koyanagi-harada syndrome in children: report of a case and review of the literature. Ocul Immunol Inflamm 2007; 15: 351-357 (Pubitemid 47347035)
30. Singsen BH, Goldbach-Mansky R. Methotrexate in the treatment of juvenile rheumatoid arthritis and other pediatric rheumatoid and nonrheumatic disorders. Rheum Dis Clin North Am 1997; 23: 811-840
31. Doycheva D, Deuter C, Stuebiger N, et al. Mycophenolate mofetil in the treatment of uveitis in children. Br J Ophthalmol 2007; 91: 180-184 (Pubitemid 46202865)
32. Greiner K, Varikkara M, Santiago C, et al. Efficiency of mycophenolate mofetil in the treatment of intermediate and posterior uveitis [in German]. Ophthalmologe 2002; 99: 691-694 (Pubitemid 36358254)
33. Dipchand AI, Benson L, McCrindle BW, et al. Mycophenolate mofetil in pediatric heart transplant recipients: a single-center experience. Pediatr Transplant 2001; 5: 112-118 (Pubitemid 32298571)
34. Siepmann K, Huber M, Stübiger N, et al. Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis. Graefes Arch Clin Exp Ophthalmol 2006; 244: 788-794
35. Baltatzis S, Tufail F, Yu EN, et al. Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. Ophthalmology 2003; 110: 1061-1065 (Pubitemid 36560514)
36. Imrie FR, Dick AD. Nonsteroidal drugs for the treatment of noninfectious posterior and intermediate uveitis. Curr Opin Ophthalmol 2007 May; 18 (3): 212-219
37. Okada AA. Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature. Ocul Immunol Inflamm 2005; 13 (5): 335-351
38. Kilmartin DJ, Forrester JV, Dick AD. Cyclosporin A therapy in refractory non-infectious childhood uveitis. Br J Ophthalmol 1998: 82 (7): 737-742 (Pubitemid 28376899)
39. Tappeiner C, Roesel M, Heinz C, et al. Limited value of cyclosporine A for the treatment of patients with uveitis associated with juvenile idiopathic arthritis. Eye 2009; 23 (5): 1192-1198
40. Miserocchi E, Baltatzis S, Ekong A, et al. Efficacy and safety of chlorambucil in intractable noninfectious uveitis: the massachusetts eye and ear infirmary experience. Ophthalmology 2002; 109: 137-142 (Pubitemid 34027437)
41. Allali F, Benomar A, Karim A, et al. Behcet's disease in Moroccan children: a report of 12 cases. Scand J Rheumatol 2004; 33: 362-363 (Pubitemid 39421223)
42. Mudun BA, Ergen A, Ipcioglu SU, et al. Short-term chlorambucil for refractory uveitis in Behcet's disease. Ocul Immunol Inflamm 2001; 9: 219-229 (Pubitemid 34286623)
43. Rosenbaum JT. Treatment of severe refractory uveitis with intravenous cyclophosphamide. J Rheumatol 1994; 21: 123-125 (Pubitemid 24044931)
44. Ardoin SP, Kredich D, Rabinovich E, et al. Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up. Am J Ophthalmol 2007; 144: 844-849 (Pubitemid 350122362)
45. Foeldvari I, Nielsen S, Kummerle-Deschner J, et al. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol 2007; 34: 1146-1150 (Pubitemid 46774863)
46. Gallagher M, Quinones K, Cervantes-Castaneda RA, et al. Biological response modifier therapy for refractory childhood uveitis. Br J Ophthalmol 2007; 91: 1341-1344 (Pubitemid 47492870)
47. Saurenmann RK, Levin AV, Rose JB, et al. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology (Oxford) 2006; 45: 982-989 (Pubitemid 44283053)
48. Kahn P, Weiss M, Imundo LF, et al. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology 2006; 113: 860-864
49. Biester S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 2007; 91: 319-324
50. Vazquez-Cobian LB, Flynn T, Lehman TJ. Adalimumab therapy for childhood uveitis. J Pediatr 2006; 149: 572-575
51. Smith JA, Thompson DJ, Whitcup SM, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005; 53: 18-23
52. Cochrane S, Dick AD. Tumor necrosis factor-alpha-targeted therapies in uveitis. In: Pleyer U, Foster CS, Weinreb RN, et al., editors. Uveitis and immunological disorders. Berlin: Springer, 2006: 9-11
53. Smith JR, Levinson RD, Holland GN, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 2001; 45: 252-257
54. Taban M, Dupps WJ, Mandell B, et al. Etanercept (enbrel)-associated inflammatory eye disease: case report and review of the literature. Ocul Immunol Inflamm 2006; 14: 145-150 (Pubitemid 43890770)
55. Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007; 56: 3248-3252 (Pubitemid 47585419)
56. Reddy AR, Backhouse OC. Does etanercept induce uveitis? Br J Ophthalmol 2003; 87 (7): 925
57. Schiff MH, Burmester GR, Kent JD, et al. Safety analyses of adalimumab (humira) in global clinical trials and us postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 889-894
58. Spillane AP, Xia Y, Sniezek PJ. Drug-induced lupus erythematosus in a patient treated with adalumimab. J Am Acad Dermatol 2007; 56: S114-6 (Pubitemid 46552083)
59. Lepore L, Marchetti F, Facchini S, et al. Drug-induced systemic lupus erythematosus associated with etanercept therapy in a child with juvenile idiopathic arthritis. Clin Exp Rheumatol 2003; 21: 276-277 (Pubitemid 36519588)
60. Sharma SM, Ramanan AV, Riley P, et al. Use of infliximab in juvenile onset rheumatological disease-associated refractory uveitis: efficacy in joint and ocular disease. Ann Rheum Dis 2007; 66: 840-841 (Pubitemid 46846714)
61. Gerloni V, Pontikaki I, Gattinara M, et al. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients. Ann Rheum Dis 2008; 67 (8): 1145-1152
62. Horneff G, Schmeling H, Biedermann T, et al. The german etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 2004; 63: 1638-1644 (Pubitemid 39573695)
63. Wallis RS. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis 2008; 8 (10): 601-611
64. Malinowski SM, Pulido JS, Folk JC. Long-term visual outcome and complications associated with pars planitis. Ophthalmology 1993; 100: 818-824
65. Burmester GR, Mease PJ, Dijkmans BA, et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis. Epub 2009 Jan 15
66. Balachandran C, McCluskey PJ, Champion GD, et al. Methotrexate-induced optic neuropathy. Clin Experiment Ophthalmol 2002 Dec; 30 (6): 440-441
67. Nestorov I. Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin Arthritis Rheum 2005; 34 (5 Suppl.1): 12-18
68. Peyrin-Biroulet L, Desreumaux P, Sandborn WJ, et al. Crohn's disease: beyond antagonists of tumour necrosis factor. Lancet 2008; 372: 67-81 (Pubitemid 351902263)
69. Murphy CC, Ayliffe WH, Booth A, et al. Tumor necrosis factor (alpha) blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 2004; 111(2): 352-356 (Pubitemid 38183244)
70. Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthamol 2005; 123 (7): 903-912 (Pubitemid 41057986)
71. Ruperto N, Lovell DJ, Cuttica R, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007; 56: 3096-3106 (Pubitemid 47502757)
72. Galor A, Perez VL, Hammel JP, et al. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 2006; 113: 2317-2323 (Pubitemid 44838928)
73. Mo JS, Matsukawa A, Ohkawara S, et al. Involvement of TNF alpha, IL-1 beta and IL-1 receptor antagonist in lps-induced rabbit uveitis. Exp Eye Res 1998; 66: 547-557
74. Shen DF, Buggage RR, Eng HC, et al. Cytokine gene expression in different strains of mice with endotoxin-induced uveitis (eiu). Ocul Immunol Inflamm 2000; 8: 221-225
75. Pascual V, Allantaz F, Arce E, et al. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005; 201: 1479-1486 (Pubitemid 40664091)
76. Verbsky JW, White AJ. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol 2004; 31 (10): 2071-2075
77. Gattorno M, Piccini A, Lasigliè D, et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 1999; 58 (5): 1505-1515
78. Teoh SC, Sharma S, Hogan A, et al. Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome. Br J Ophthalmol 2007; 91: 263-264 (Pubitemid 46202883)
79. Arostegui JI, Arnal C, Merino R, et al. Nod2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a spanish cohort. Arthritis Rheum 2007; 56: 3805-3813 (Pubitemid 350100713)
80. Hull KM, Shoham N, Chae JJ, et al. The expanding spectrum of systemic autoinflammatory disorders and their rheumatic manifestations. Curr Opin Rheumatol 2003; 15: 61-69 (Pubitemid 36021025)
81. Matsubayashi T, Sugiura H, Arai T, et al. Anakinra therapy for CINCA syndrome with a novel mutation in exon 4 of the cias1 gene. Acta Paediatr 2006; 95: 246-249 (Pubitemid 43189022)
82. Seitz M, Kamgang RK, Simon HU, et al. Therapeutic interleukin (IL) 1 blockade normalises increased IL1 beta and decreased tumour necrosis factor alpha and IL10 production in blood mononuclear cells of a patient with CINCA syndrome. Ann Rheum Dis 2005; 64: 1802-1803
83. Matsubara T, Hasegawa M, Shiraishi M, et al. A severe case of chronic infantile neurologic, cutaneous, articular syndrome treated with biologic agents. Arthritis Rheum 2006; 54: 2314-2320 (Pubitemid 44051090)
84. Martin TM, Zhang Z, Kurz P, et al. The NOD2 defect in Blau syndrome does not result in excess interleukin-1 activity. Arthritis Rheum 2009; 60 (2): 611-618
85. Milman N, Andersen CB, Hansen A, et al. Favourable effect of TNF-alpha inhibitor (infliximab) on Blau syndrome in monozygotic twins with a de novo CARD15 mutation. APMIS 2006; 114 (12): 912-919 (Pubitemid 44967328)
86. Hawkins PN, Lachmann HJ, Aganna E, et al. Spectrum of clinical features in muckle-wells syndrome and response to anakinra. Arthritis Rheum 2004; 50: 607-612 (Pubitemid 38198844)
87. Nussenblatt RB, Fortin E, Schiffman R, et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-tac mab: a phase I/II clinical trial. Proc Natl Acad Sci U S A 1999; 96: 7462-7466 (Pubitemid 29299684)
88. Guex-Crosier Y, Raber J, Chan CC, et al. Humanized antibodies against the alpha-chain of the IL-2 receptor and against the beta-chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases. J Immunol 1997; 158: 452-458 (Pubitemid 127483888)
89. Nussenblatt RB, Thompson DJS, Li Z, et al. Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun 2003; 21: 283-293 (Pubitemid 37410117)
90. Yeh S, Wroblewski K, Buggage R, et al. High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis. J Autoimmun 2008; 31 (2): 91-97
91. Buggage RR, Levy-Clarke G, Sen HN, et al. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to behcet's disease. Ocul Immunol Inflamm 2007; 15: 63-70 (Pubitemid 46897689)
92. Smith JM, Nemeth TL, McDonald RA. Current immunosuppressive agents in pediatric renal transplantation: efficacy, side-effects and utilization. Pediatr Transplant 2004; 8: 445-453
93. Patten SB. Psychiatric side effects of interferon treatment. Curr Drug Saf 2006; 1 (2): 143-150
94. Plskova J, Greiner K, Muckersie E, et al. Interferon-alpha: a key factor in autoimmune disease? Invest Ophthalmol Vis Sci 2006; 47: 3946-3950
95. Okada AA, Keino H, Fukai T, et al. Effect of type I interferon on experimental autoimmune uveoretinitis in rats. Ocul Immunol Inflamm 1998; 6: 215-226 (Pubitemid 29043745)
96. Selmi C, Lleo A, Zuin M, et al. Interferon alpha and its contribution to autoimmunity. Curr Opin Investig Drugs 2006; 7: 451-456 (Pubitemid 43772985)
97. Pivetti-Pezzi P, Accorinti M, Pirraglia MP, et al. Interferon alpha for ocular behcet's disease. Acta Ophthalmol Scand 1997; 75: 720-722 (Pubitemid 28102747)
98. Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon alfa-2a in the treatment of behcet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol 2002; 138: 467-471 (Pubitemid 34290024)
99. Wechsler B, Bodaghi B, Huong DL, et al. Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behcet's disease. Ocul Immunol Inflamm 2000; 8 (4): 293-301 (Pubitemid 32174750)
100. Krause L, Turnbull JR, Torun N, et al. Interferon alfa-2a in the treatment of ocular Adamantiades-Behcet's disease. Adv Exp Med Biol 2003; 528: 511-519
101. Krause L, Altenburg A, Pleyer U, et al. Long-term visual prognosis of patients with ocular Adamantiades-Behcet's disease treated with interferon-alpha-2a. J Rheumatol 2008; 35 (5): 896-903 (Pubitemid 351747134)
102. Guillaume-Czitrom S, Berger C, Pajot C, et al. Efficacy and safety of interferon-alpha in the treatment of corticodependent uveitis of paediatric Behcet's disease. Rheumatology (Oxford) 2007; 46: 1570-1573 (Pubitemid 47500572)
103. Iorio R, Pensati P, Botta S, et al. Side effects of alpha-interferon therapy and impact on health-related quality of life in children with chronic viral hepatitis. Pediatr Infect Dis J 1997; 16 (10): 984-990 (Pubitemid 27452318)
104. BallauffA, Schneider T,Gerner P, et al. Safety and efficacy of interferon retreatment in children with chronic hepatitis B. Eur J Pediatr 1998; 157: 382-385 (Pubitemid 28225439)
105. Heiligenhaus A, Niewerth M, Mingels A, et al. Epidemiology of uveitis in juvenile idiopathic arthritis from a national paediatric rheumatologic and ophthalmologic database [in German]. Klin Monatsbl Augenheilkd 2005; 222: 993-1001 (Pubitemid 43058456)
106. Rosenberg KD, Feuer WJ, Davis JL. Ocular complications of pediatric uveitis. Ophthalmology 2004; 111: 2299-2306
107. Menezo V, Lau C, Comer M, et al. Clinical outcome of chronic immunosuppression in patients with non-infectious uveitis. Clin Experiment Ophthalmol 2005; 33: 16-21 (Pubitemid 40330970)
108. Zerkak D, Dougados M. Benefit/risk of combination therapies. Clin Exp Rheumatol 2004; 22: S71-6
109. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The premier study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54: 26-37
110. Pijpe J, van Imhoff GW, Spijkervet FK, et al. Rituximab treatment in patients with primary sjogren's syndrome: an open-label phase II study. Arthritis Rheum 2005; 52: 2740-2750 (Pubitemid 41369102)
111. El Fassi D, Nielsen CH, Bonnema SJ, et al. B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study. J Clin Endocrinol Metab 2007; 92: 1769-1772 (Pubitemid 46997186)
112. Kuek A, Hazleman BL, Gaston JH, et al. Successful treatment of refractory polyarticular juvenile idiopathic arthritis with rituximab. Rheumatology (Oxford) 2006; 45: 1448-1449 (Pubitemid 44605487)
113. Ishikawa H. Mizoribine and mycophenolate mofetil. Ishikawa H. Curr Med Chem 1999; 6 (7): 575-597
114. Yoshioka K, Ohashi Y, Sakai T, et al. A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome. Kidney Int 2000; 58: 317-324 (Pubitemid 30429877)
115. Ito S, Harada T, Nakamura T, et al. Mizoribine for renal sarcoidosis: effective steroid tapering and prevention of recurrence. Pediatr Nephrol 2009 Feb; 24 (2): 411-414
116. Tanaka H, Oki ES, Tsugawa K, et al. Long-term intermittent pulse therapy with mizoribine attenuates histologic progression in young patients with severe lupus nephritis: report of two patients. Nephrology (Carlton) 2007; 12 (4): 376-379 (Pubitemid 47075410)
117. Hayashi A, Hanada T, Kohda T, et al. Mizoribine oral pulse therapy for a patient with polyarticular juvenile idiopathic arthritis. Pediatr Int 2006; 48: 638-640 (Pubitemid 44813416)
118. De Kozak Y, Omri B, Smith JR, et al. Protein kinase Czeta (PKCzeta) regulates ocular inflammation and apoptosis in endotoxin-induced uveitis (EIU): signaling molecules involved in EIU resolution by PKCzeta inhibitor and interleukin-13. Am J Pathol 2007 Apr; 170 (4): 1241-1257 (Pubitemid 47339332)
119. Houslay MD, Schafer P, Zhang KY. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today 2005 Nov; 10 (22): 1503-1519 (Pubitemid 41527193)
120. Rapoff MA, Lindsley CB. Improving adherence to medical regimens for juvenile rheumatoid arthritis. Pediatr Rheumatol Online J 2007; 5: 10